Fractyl Health

GUTS on Nasdaq. Fractyl Health develops treatments for people with obesity and type 2 diabetes. Market value $726m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
-12.5%low

For every $100 of what the whole company costs, it produced $-12.49 of spare cash last year. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$4.57 a share, 6% above its 1-year low

Over the past year the price has ranged from $4.33 to $29.34.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
20242025
Revenue
$93,000$0
Operating margin
-100571.0%n/a
Debt to equity
n/an/a
Shares outstanding
0.14bn0.16bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)2 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 16% more shares since 2024

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $26 million, compared with a loss of $28 million a year ago.
  • 223% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$23m
December 2024-$25m
March 2025-$24m
June 2025-$28m
September 2025-$46m
December 2025-$44m
March 2026$9m
June 2026-$26m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 March 2026
Next quarterly (estimated, 10-Q)
9 November 2026

Who owns it

None of the long-term investors we follow own it. 76 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

  • at least 10.0%0.0 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • Deer VII & Co. Ltd.
    Passive investor
    at least 9.9%
    (filed with 3 related holders)
    Since 31 December 2024
  • at least 5.0%−4.7 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • at least 4.8%−0.5 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • Ajay Royan
    Passive investor
    at least 4.7%
    (filed with 6 related holders)
    Since 31 December 2025
  • HCC Manager LLC
    Passive investor
    at least 3.4%
    (filed with 1 related holder)
    Since 4 February 2026
  • Maverick Capital, Ltd.
    Passive investor
    at least 3.1%
    (filed with 2 related holders)
    Since 30 September 2025
  • BlackRock, Inc.
    Passive investor
    Sold down below 5%
    Since 31 March 2025
  • Sold down below 5%
    Since 31 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 5 insiders bought $187,052 of shares on the open market.

  • BRADLEY WILLIAM
    Director
    Bought
    Date
    14 September 2026
    Shares
    64,516
    Price
    $0.62
    Value
    $39,903
  • Royan Ajay
    Director
    Bought
    Date
    12 June 2026
    Shares
    23,000
    Price
    $0.85
    Value
    $19,550
  • BRADLEY WILLIAM
    Director
    Bought
    Date
    10 June 2026
    Shares
    68,493
    Price
    $0.73
    Value
    $50,000
  • Sheffield Ian
    Director
    Bought
    Date
    10 June 2026
    Shares
    35,000
    Price
    $0.73
    Value
    $25,550
  • Rajagopalan Harith
    Chief Executive Officer, Director
    Bought
    Date
    10 June 2026
    Shares
    25,000
    Price
    $0.73
    Value
    $18,250
  • Smith Weber Lara
    Chief Financial Officer
    Bought
    Date
    8 June 2026
    Shares
    20,000
    Price
    $0.69
    Value
    $13,800
  • Rajagopalan Harith
    Chief Executive Officer, Director
    Bought
    Date
    4 December 2025
    Shares
    10,416
    Price
    $1.92
    Value
    $19,999

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Fractyl Health’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 9 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “As a result, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
    Show the full paragraph
    The Company has financed its operations to date primarily through its equity and debt financings. The Company has a history of operating losses and had an accumulated deficit of $ 572.6 million as of June 30, 2026, and management expects continuing operating losses in the future. As of June 30, 2026 , the Company had available cash and cash equivalents of $ 47.1 million. Management believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early 2027, through multiple key clinical and regulatory milestones. However, these existing cash resources are not expected to be sufficient to fund the Company’s current operating plan for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year after the date that these financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

    From the 10-Q filed 10 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.